Menu

Probing Canine Face Recognition

Dogs trained to stay still in an MRI machine show activity in the temporal cortex when shown a human face.

Mar 4, 2016
Jef Akst

L.V. CUAYA ET AL., PLOS ONEResearchers from the National Autonomous University of Mexico have studied the brains of seven dogs trained to lie down but stay attentive inside an MRI scanner. The team presented the animals with photos of human faces or of objects. The object images elicited very little brain activity, but the human pictures triggered a burst of activity: the bilateral temporal cortex lit up the most, and the team saw additional activity in the frontal cortex, the caudate nucleus, and the thalamus.

“This portion of the temporal cortex in dogs could be anatomically and functionally similar to regions found in other species, like humans, non-human primates and sheep, which suggests a high degree of evolutionary conservation of the ventral visual pathway for face processing,” the researchers wrote in their paper, published this week (March 2) in PLOS ONE.

Studies of how dogs recognize human faces, then, may inform our understanding of human facial perception. A study from February 2015, for example, tested dogs’ ability to identify emotional expressions when shown pictures of just one half a human face, and the canines performed well.

“The recognition of human faces by dogs could be an essential factor for establishing attachment with humans,” the authors of the new PLOS ONE study wrote in their paper.

The idea of putting dogs in an MRI machine to probe their brain activity during different tasks started with Emory University neuroscientist Gregory Berns, who in 2012 trained two dogs (including his own) to stay still while remaining alert, then presented the animals with an indication that food was coming. In this experiment, Berns recorded activity in the canines’ caudate nucleus, a brain region associated with reward processing. Last August, Berns and his colleagues tested six dogs in the MRI scanner and found that their temporal cortices responded much more to movies of human or dog faces than to movies of objects, supporting the Mexico group’s latest findings.

“[T]hese findings . . . may help explain dogs’ exquisite sensitivity to human social cues,” Berns and his colleagues wrote in their paper, published in PeerJ.

Hat tip: RealClearScience

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.